Episurf Medical announced that the company's 510(k) application to the US FDA for market clearance for the Episealer® Patellofemoral System now is progressing to the substantive review phase.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.444 SEK | +16.84% | +18.72% | -55.15% |
04-24 | Episurf Medical Announces Distributor Agreement with Depuy-Synthes | CI |
04-24 | Episurf Medical AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-55.15% | 9.41M | |
+8.70% | 125B | |
+6.05% | 8.93B | |
+23.36% | 7.57B | |
+32.10% | 5.36B | |
+8.61% | 3.43B | |
-9.10% | 2.81B | |
-2.71% | 2.23B | |
-0.20% | 2.13B | |
-20.42% | 1.84B |
- Stock Market
- Equities
- EPIS B Stock
- News Episurf Medical AB
- Episurf Medical Provides Updates of 510(K) Application on Episealer Patellofemoral System